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Abstract
Objectives: To investigate subcutaneous blood flow rate (SBFR) in healthy volunteers and patients
with severe motor and intellectual disabilities (SMID), and evaluate the effect of mentholated warm
compresses (MWCs) on SBFR and subcutaneous ceftazidime absorption in healthy volunteers.
Methods: SBFR at the forearm, chest and abdomen were evaluated in Japanese healthy volunteers
and in adults with SMID. The effects of MWCs on blood flow rate and ceftazidime pharmaco-
kinetics were evaluated in healthy volunteers.
Results: SBFR was significantly lower in the forearms of female patients with SMID (n¼ 11) than in
the forearms of healthy females (n¼ 6); it was not significantly lower in the abdomen or chest.
There were no significant differences between male patients (n¼ 18) or controls (n¼ 12) in SBFR
at any site. MWC application increased SBFR 1.3- to 2.0-fold compared with baseline in healthy
controls (n¼ 6). MWC application increased ceftazidime maximum blood concentration, SBFR and
time above mutant prevention concentration in a single healthy subject.
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Conclusions: Abdominal SBFR in patients with SMID did not differ from that of healthy subjects.
MWC application increases SBFR and subcutaneous drug absorption rate in healthy humans.
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Introduction
Patients with severe motor and intellectual
disabilities (SMID) may have complications
including cerebral palsy, scoliosis, epilepsy,
abnormal muscle tone, dysphagia, respira-
tory problems and various digestive dis-
orders.1 They may also experience elevated
heart rate, impaired blood pressure regula-
tion or respiratory function, and reduced
circulating blood volume. In addition, long
periods of motor disruption may cause
patients to become bedridden, and this
often leads to disuse syndrome.
Pneumonia, particularly aspiration pneu-
monia, is the leading cause of death in
patients with SMID.2 Maintaining anti-
biotic concentrations within the therapeutic
range facilitates recovery and prevents drug
resistance, but this is a signiﬁcant challenge.
Patients with SMID have a hyperactive
sympathetic nervous system, causing vaso-
constriction and reduced blood ﬂow; this
makes it diﬃcult to locate veins for intra-
venous administration of drugs, including
antibiotics.3 Venepuncture may take exces-
sive time or may not even be possible due to
narrowing of the vascular diameter.
We have previously reported the use of
subcutaneous antibiotic injection as an
alternative to intravenous administration
for treatment of pneumonia in patients
with SMID.4 Subcutaneous administration
is more accessible and less painful than
intravenous administration; it also reduces
the risk of tissue damage, which is
particularly important given the reduced
muscle volume associated with long-term
bed rest in patients with SMID.5 The plasma
concentration of ceftazidime, a third-
generation cephalosporin widely used in
the treatment of aspiration pneumonia,
exceeded the minimum concentration
required for inhibiting 90% of bacterial
growth (MIC90), while remaining below
the mutant prevention concentration
(MPC; the minimum concentration required
to prevent the development of bacterial
resistance) in guinea pigs injected with
naphazoline nitrate to simulate SMID
haemodynamics.4 Doubling the administra-
tion rate or concentration of ceftazidime
increased the plasma concentration above
MIC90 and MPC,4 but these results could
not be applied clinically because doubling
the administration rate causes pain at the
injection site.6,7
The application of mentholated warm
compresses (MWCs) to the ceftazidime
administration site ameliorated the eﬀect of
naphazoline nitrate on blood ﬂow in our
animal model, resulting in plasma ceftazi-
dime concentrations exceeding MIC90 and
MPC without increasing the drug adminis-
tration rate.4 It is not known whether this
ﬁnding would be observed in humans,
however.
The aim of this present study was to
investigate whether the ﬁndings of our
animal study are replicated in humans.
Subcutaneous blood ﬂow rate in healthy
volunteers and patients with SMID was
Ebihara et al. 249
investigated and the eﬀect of MWCs on
blood ﬂow rate in healthy volunteers was
evaluated. In addition, change in plasma
drug concentration over time was analysed
after application of MWCs in a healthy
volunteer, in order to evaluate the associ-
ation between subcutaneous absorption rate
and blood ﬂow rate.
Patients and methods
Study population
The study enrolled adult patients with
SMID, resident since childhood at the
National Rehabilitation Centre for
Children with Disabilities, Tokyo, Japan.
The study was conducted between 24 April
2012 and 29 May 2012. Patients who were
considered suitable for inclusion and those
for whom consent was provided were
enrolled. Healthy adult volunteers were
recruited from the staﬀ at the National
Rehabilitation Centre for Children with
Disabilities, and also from Josai University
in Saitama, Japan. Control subjects were
required to not be attending any clinic or
taking any regular medication.
The study protocol was approved by the
Ethics Review Committee of the National
Rehabilitation Centre for Children with
Disabilities (approval date: 25 October
2010). All healthy participants and families
of participants with SMID provided written
informed consent.
Subcutaneous blood flow rate
measurement
All participants were placed at rest in the
supine position for at least 15min, then
blood ﬂow rate was measured using laser
Doppler blood ﬂowmetry (moorVMS-
LDF1, Moor-Instruments Ltd, Devon,
UK). Measuring probes (VP1T) were
adhered with 5-cm double-sided tape to the
measurement sites (forearm, 10 cm from the
medial wrist joint to the elbow; abdomen,
3 cm lateral from the umbilical region; chest,
from the clavicular and manubrium junction
to immediately below), to measure blood
ﬂow rate for 3min. The laser characteristics
were as follows: 780 nm wavelength; 20–
22 kHz bandwidth; 0.1 s time constant;
40Hz sampling frequency. Data were trans-
ferred to a data analysis system (moorVMS-
PC, Ver3.0, Moor-Instruments, Ltd), and a
180-s mean value representing the steady
blood ﬂow rate was computed. Each par-
ticipant’s blood ﬂow was measured under
quiet conditions, adjusted to 22–26C.
Subcutaneous blood flow enhancement
Mentha oil (0.5ml; Yoshida Pharmaceutical
Co., Ltd, Tokyo, Japan) was added to hot
water (500ml, 65C) to make a 0.1% men-
thol emulsion. To prepare the MWCs,
towels (19 cm 16 cm, with a 6-cm diameter
hole in the centre for attaching the blood
ﬂow-measuring probe) were immersed in the
menthol emulsion until they reached 65C in
temperature.
A subset of six healthy adult subjects
were placed at rest in the supine position for
at least 15min. Blood ﬂow was then mea-
sured for 10min at the MWC abdominal
application site (6 cm left lateral of the
umbilical region), and the mean skin blood
ﬂow rate at rest (baseline) was calculated.
Next, theMWCwas applied to the abdomen
and the entire towel was wrapped with
plastic wrap to prevent evaporation of the
menthol emulsion. The MWC was replaced
eight times (once every 10min) for a total
application time of 90min. To maintain the
towels’ temperature at 65C, each MWC
was prepared just before adhesion. Blood
ﬂow rate and skin surface temperature were
recorded every 0.5 s over 120min (for the
90min adhesion period and 30min after
removal). Mean blood ﬂow rate and mean
skin surface temperature were calculated
every minute and recorded as the blood
ﬂow rate and skin surface temperature,
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respectively. To evaluate the eﬀect ofMWCs
on blood ﬂow rate, changes in blood ﬂow
rate were calculated as a percentage of blood
ﬂow rate value compared with baseline.
Ceftazidime pharmacokinetics
The abdominal blood ﬂow rate of a healthy
male subject was measured for 10min at
rest, after which an MWC was applied
for 90min. Continuous ceftazidime subcuta-
neous administration (Modacin; Glaxo
SmithKline K.K., Tokyo, Japan) began at
the left abdominal site 60min after the start
of MWC application (administration rate:
0.5 g/10ml per 30min 2 sites). Using ethy-
lenediaminetetra-acetic acid disodium as an
anticoagulant, 8ml blood was collected
before ceftazidime administration and at
10, 20, 30, 60, 90, 120, 180 and 240min
after the start of administration. Collected
blood was centrifuged (4C, 3000g,
10min) for plasma isolation and stored at
45C until ceftazidime concentration was
determined.
Plasma (0.75ml) was mixed with an equal
volume of 7% perchloric acid and centri-
fuged (4C, 13,000 g, 15min). The resulting
supernatant (20 ml) was diluted with metha-
nol as needed. Plasma ceftazidime concen-
tration was determined via high
performance liquid chromatography
(HPLC), as previously described.4 The cali-
bration curve was created from 0.02, 0.05,
0.1, 0.2, 0.5, 1, 2, 5 and 10 mg/ml ceftazidime,
and linearity was conﬁrmed within this
concentration range.
Each parameter of the ceftazidime
absorption proﬁle was calculated with the
use of a one-compartment model using
MULTI (algorithm; Simplex method), a
program using the nonlinear least squares
method.8 The cumulative absorption rate
was estimated through deconvolution of
pharmacokinetic parameters and plasma
concentration data collected after intraven-
ous administration in healthy volunteers.9–11
Statistical analyses
Data were presented as meanSEM.
Biometric data were compared using
Student’s t-test. Comparisons of blood
ﬂow rate in patients with SMID and healthy
volunteers were made using two-way ana-
lysis of variance (ANOVA) with paired
comparison for one factor (factor A: healthy
volunteers or patients with SMID; factor B:
forearm, chest or abdomen). When ANOVA
showed a signiﬁcant eﬀect (P< 0.05), means
were compared with Tukey’s honest signiﬁ-
cant diﬀerence post-hoc test. P-values< 0.05
were considered statistically signiﬁcant. All
analyses were performed using R version
2.15.2 (R Foundation for Statistical
Computing, Vienna, Austria) for
Windows.12
Results
The study enrolled 41 healthy adults (16
male/25 female; mean age 45.7 1.30 years;
age range 21–58 years) and 48 patients with
SMID (23 male/25 female; mean age
45.9 1.28 years; age range 22–70 years).
Blood ﬂow rate analysis was performed
using data obtained from 40- to 54-year-
old male and 45- to 49-year-old female
patients (control group: 12 male/six female;
SMID group: 18 male/11 female), who
formed the largest subpopulation in the
SMID group. Biometric data for this sub-
population are shown in Table 1. There
were signiﬁcant between-group diﬀerences
in height, weight and body mass index
(BMI) for both sexes (P< 0.001 for each
comparison). There was no signiﬁcant
between-group diﬀerence in age for both
sexes.
A sex-based comparison of blood ﬂow
rates at each site is shown in Table 2. In both
healthy male and female subjects, blood ﬂow
rate was signiﬁcantly higher in the forearm
than in both the chest and abdomen
(P< 0.01 for each comparison). There were
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no signiﬁcant between-site diﬀerences in
blood ﬂow rate in male or female patients
with SMID.
Blood ﬂow rate in the forearm was
signiﬁcantly lower in female patients with
SMID than it was in healthy female volun-
teers (P< 0.001). There was no signiﬁcant
between-group diﬀerence in blood ﬂow rate
at any site in males, or at the chest and
abdomen in females.
Data regarding changes in blood ﬂow
rate and skin surface temperature following
MWC application in a subset of six healthy
volunteers are shown in Figure 1. Skin
surface temperature increased by 15–20%
following MWC application in each sub-
ject, and then gradually decreased until
MWCs were replaced. This change was
observed repeatedly until completion of
MWC treatment, at which time skin sur-
face temperature slowly decreased. Blood
ﬂow rate was increased relative to baseline
following MWC application in each sub-
ject, although changes varied among sub-
jects. In subjects 1–4, blood-ﬂow rate
increased immediately after MWC applica-
tion. In comparison, subjects 5 and 6 began
showing moderate elevation after 20min.
Table 1. Biometric characteristics of males aged 40–54 years and females aged 45–49 years included in a
Japanese study investigating subcutaneous blood flow rate in healthy volunteers and patients with severe
motor and intellectual disabilities (SMID), stratified according to sex.
Characteristic









Age, years 48.8 0.97 46.3 1.01 46.8 0.70 47.2 0.54
Height, cm 171.2 1.43 152.4 2.14*** 157.8 2.01 142.2 3.03***
Weight, kg 69.1 2.17 35.5 1.84*** 52.7 2.59 32.5 1.81***
BMI, kg/m2 23.6 0.74 15.1 0.56*** 21.2 1.10 15.9 0.60***
Data presented as mean SEM.
BMI, body mass index.
***P< 0.001 versus same-sex healthy group; Student’s t-test.
Table 2. Subcutaneous blood flow rates in healthy volunteers and patients with severe motor and
intellectual disabilities (SMID) included in a Japanese study investigating subcutaneous blood flow rate in
healthy volunteers and patients with SMID, stratified according to sex.
Injection site









Forearm 36.9 7.67c,d 21.6 5.46 50.0 9.32e,f 17.1 1.60g
Chest 19.7 2.38 16.7 0.89 16.8 1.28 17.4 1.39
Abdomen 12.5 1.62 15.8 1.28 11.6 0.57 18.1 2.06
Data presented as mean SEM.
aAged 40–54 years; baged 45–49 years; cP< 0.01 vs chest in same group; dP< 0.01 vs abdomen in same group; eP< 0.001 vs
chest in same group; fP< 0.001 vs abdomen in same group; gP< 0.001 vs same site in healthy female subjects; Tukey’s honest
significant difference post-hoc test.
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Blood ﬂow rate increased 1.3- to 2.0-fold
in all subjects after MWC application
(Figure 2).
The eﬀects of MWCs on ceftazidime
pharmacokinetics in a single healthy subject
are shown in Figure 3. Ceftazidime plasma
concentration rapidly increased and reached
the maximum (Cmax) within 90min of
subcutaneous administration, regardless of
MWC application (Figure 3a). The Cmax
was 44.8mg/ml without MWC application,
and 57.4mg/ml with MWCs. The duration
that MPC (32mg/ml) was exceeded was
182.2min with MWCs and 130.7min with-
out; this is a diﬀerence of 51.5min
(Figure 3a). The time to complete absorp-
tion was 120min with MWCs and 205min
without (Figure 3b). The eﬀect of MWC
application on blood ﬂow rate in this indi-
vidual is shown in Figure 3c. Flow rate
rapidly elevated when MWCs were applied,
peaking at 185.9% of the baseline value
immediately before subcutaneous ceftazi-
dime administration (55min after applica-
tion). Although the ﬂow rate moderately
declined after cessation of MWC treatment,
it remained above the baseline value until
blood collection was completed.
Discussion
Intravenous drug administration is the pre-
ferred method when there is a need for rapid
achievement of therapeutic blood concen-
trations. Narrow vascular diameters in some
patients with SMID may complicate
Figure 1. Effect of mentholated warm compresses (MWCs) on subcutaneous blood flow rate in Japanese
healthy volunteers (n¼ 6) in a study investigating subcutaneous blood flow rate in healthy volunteers and
patients with severe motor and intellectual disabilities, stratified according to sex. In each graph, the X-axis
indicates minutes and the Y-axis represents either the blood flow relative to baseline or skin surface
temperature (C). n, application of MWC.
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intravenous injection, resulting in missed
venepuncture and undue pain.
Studies investigating absorption into sys-
temic circulation via subcutaneous (rather
than intravenous) administration have indi-
cated that absorption rate may depend on
subcutaneous blood ﬂow.13,14 The small
arteries and veins in the skin, prevalence of
arteriovenous anastomotic branches, high
pressure on the smaller artery walls and
distensibility of the venous walls allow the
thermoregulatory function to signiﬁcantly
alter blood ﬂow to the skin. Changes in
cutaneous blood ﬂow through constriction
and distention of blood vessels in the skin
are controlled by neural factors (e.g. the
skin’s sympathetic nerves) and environmen-
tal factors (e.g. the local temperature).15
Since the sympathetic nervous system in
patients with SMID is reportedly enhanced
compared with that of healthy subjects,16,17
cutaneous blood vessels may be constricted,
resulting in reduced blood ﬂow.
The present study evaluated subcutane-
ous blood ﬂow rates in the forearm, abdo-
men and chest, as candidate sites for
subcutaneous ceftazidime administration.
Blood ﬂow rate was signiﬁcantly lower in
the forearms of women with SMID than in
the forearams of healthy female volunteers;
this was possibly due to vasoconstriction.
This ﬁnding enforces that it is diﬃcult to
distinguish veins for venepuncture in
patients with SMID. There were no signiﬁ-
cant between-group diﬀerences in blood
ﬂow rate in the abdomen or chest, however,
demonstrating that subcutaneous blood
ﬂow rate in patients with SMID does not
always diﬀer from that in healthy volun-
teers; it depends on the site being evaluated.
Figure 2. Change in subcutaneous blood flow rate relative to baseline in six healthy Japanese volunteers
following application of mentholated warm compresses (in a study investigating subcutaneous blood flow rate
in healthy volunteers and patients with severe motor and intellectual disabilities, stratified according to sex).
AUC0–90, area under the blood flow rate-time curve from 0 to 90min; AUCBL, area under the baseline blood
flow rate-time curve from 0 to 90min.
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The present ﬁnding that the application
of MWCs increased blood ﬂow rate in
healthy subjects conﬁrms the results of
our animal study.4 It has been reported
that blood ﬂow rate in the right forearm
rises rapidly to approximately 2.5 times
the baseline value following application of
2% menthol in white petrolatum.18
Similarly, application of 3% menthol
increased blood ﬂow, possibly via direct
action of menthol against Transient
Receptor Potential M8 (TRPM8; present
on blood vessel walls).19 If menthol does
increase blood ﬂow via TRPM8, individual
response may vary depending on the levels
of this protein.
In pharmacotherapy, the plasma drug
concentration of antibiotics should be
Figure 3. Effect of mentholated warm compresses (MWCs) on subcutaneous absorption of 1.0 g/30min
ceftazidime (CAZ) in a Japanese healthy volunteer (n¼ 1) taking part in a study investigating subcutaneous
blood flow rate in healthy volunteers and patients with severe motor and intellectual disabilities, stratified
according to sex. (a) Ceftazidime plasma concentration-time curves. , with MWCs; * without MWCs.
(b) Cumulative ceftazidime absorption, determined by deconvolution method. (c) Changes in subcutaneous
blood flow rate. MPC, mutant prevention concentration (minimum concentration required to prevent the
development of bacterial resistance).
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maintained above the MPC to prevent
emergence of resistant bacteria.
Subcutaneous administration of ceftazidime
combined with MWC application sustained
plasma concentrations above the MPC for a
longer period than without MWCs.
Notably, the subjects’ skin surface tempera-
tures never exceeded 45C during MWC
application, which would have caused burn
injuries. Thus, MWCs may be considered a
safe enhancer of absorption for subcutane-
ously administered drugs.20 There were sig-
niﬁcant diﬀerences between patients and
controls in physical characteristics
(including body weight and BMI) in the
present study, making it diﬃcult to extrapo-
late our ﬁndings regarding the eﬀect of
MWCs on blood ﬂow in healthy subjects
to patients with SMID.
In conclusion, this study demonstrates
that MWC application increases the sub-
cutaneous blood ﬂow rate and subcutaneous
drug absorption rate in healthy humans. It
was expected that blood ﬂow rate would be
lower in patients with SMID than in healthy
subjects, regardless of measurement pos-
ition, but this was not the case.
Subcutaneous blood ﬂow rate at the abdo-
men (a candidate site for subcutaneous
administration) was not signiﬁcantly diﬀer-
ent in patients with SMID and healthy
subjects. Further studies are required to
determine whether the application of
MWCs increases the blood ﬂow rate and
absorption rate of subcutaneous ceftazidime
in patients with SMID.
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